Lahore: Citi Pharma Limited has scheduled its Annual General Meeting (AGM) to take place on October 28, 2026, at 12:30 p.m. at its head office located in Johar Town, Lahore. The meeting will focus on key financial and administrative decisions for the upcoming year.

The agenda for the AGM includes confirming the minutes from the last Extra Ordinary General Meeting held on September 18, 2026. Additionally, the meeting will address the adoption of the Company's Audited Financial Statements, along with the Consolidated Audited Financial Statements for the fiscal year ending June 30, 2026. These documents come with accompanying reports from the auditors, directors, and the chairman.

In a significant financial decision, the Board of Directors has opted not to recommend any dividend for the fiscal year ended June 30, 2026. This decision follows an analysis of the Company's profitability, cash generation, working-capital needs, planned capital expenditures, and future funding requirements.

Another crucial item on the agenda is the appointment of statutory auditors for the fiscal year ending June 30, 2027. The Board has recommended the re-appointment of M/s Aslam Malik & Co., Chartered Accountants, following the Audit Committee's endorsement. The remuneration for the auditors will be determined through mutual agreement, with reimbursement for out-of-pocket expenses based on actual costs.

According to information available from the Pakistan Stock Exchange (PSX), Citi Pharma Limited continues to be a notable entity within the designated market category, reflecting its operational and financial activities.

The meeting will also leave room for any other business discussions, pending permission from the chair. This comprehensive approach underscores the Company's commitment to transparency and strategic governance.